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Objectives: The combination use of geﬁtinib and epidermal growth factor receptor (EGFR) testing is a
standard ﬁrst-line therapy for patients with non-small cell lung cancer (NSCLC). Here, we examined the
cost-effectiveness of this approach in Japan.
Materials andmethods:Our analysis compared the ‘EGFR testing strategy’, inwhich EGFRmutation testing
wasperformedbefore treatment andpatientswithEGFRmutations receivedgeﬁtinibwhile thosewithout
mutations received standard chemotherapy, to the ‘no-testing strategy,’ in which genetic testing was not
conducted and all patients were treated with standard chemotherapy. A three-state Markov model was
constructed to predict expected costs and outcomes for each strategy. We included only direct medical
costs from the healthcare payer’s perspective. Outcomes in the model were based on those reported in
the Iressa Pan-Asia Study (IPASS). The incremental cost-effectiveness ratio (ICER) was calculated using
quality-adjusted life-years (QALYs) gained. Sensitivity and scenario analyses were conducted.
Results: The incremental cost and effectiveness per patient of the ‘EGFR testing strategy’ compared to
the ‘no-testing strategy’ was estimated to be approximately JP¥122,000 (US$1180; US$1= JP¥104 as of
February 2014) and 0.036 QALYs. The ICER was then calculated to be around JP¥3.38 million (US$32,500)
per QALY gained. These results suggest that the ‘EGFR testing strategy’ is cost-effective compared with
the ‘no-testing strategy’ when JP¥5.0 million to 6.0 million per QALY gained is considered an acceptable
threshold. These results were supported by the sensitivity and scenario analyses.
Conclusion: The combination use of geﬁtinib and EGFR testing can be considered a cost-effective ﬁrst-line
therapy compared to chemotherapy such as carboplatin–paclitaxel for the treatment for NSCLC in Japan.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Lung cancer is the most common cause of death from cancer
worldwide, representing nearly 20% of all cancer deaths [1]. In
Japan, lung cancer is the leading causeof death, accounting formore
than 70,000 deaths in 2013, and both the morbidity and mortal-
ity continue to increase [2]. Thus, lung cancer is one of the most
important public health issues.
Approximately 80% of all lung cancer cases are non-small cell
lung cancer (NSCLC). The majority of patients with NSCLC are
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diagnosed at an advanced stage [3,4]. Standard ﬁrst-line therapy
for advanced NSCLC consists of systemic platinum-based doublet
chemotherapy, including cisplatin or carboplatin, combined with
taxanes, pemetrexed and gemcitabine. Although several combina-
tions are used, none has yet shown superiority [5–7].
Recently, targeted therapies have been developed to provide
alternative treatment options for this disease. Geﬁtinib is an orally
administered epidermal growth factor receptor tyrosine kinase
inhibitor (EGFR-TKI) which was ﬁrst approved in Japan in 2002.
In 2004, two pivotal studies revealed that the presence of genetic
mutation in the kinase domain of EGFR strongly correlates with
increased responsiveness to EGFR-TKI [8,9]. Subsequently, four
randomized Phase 3 clinical trials, including the Iressa Pan-Asia
Study (IPASS), assessed geﬁtinib as ﬁrst-line therapy for advanced
NSCLC patients with EGFR mutation [10–13]. In the subgroup of
patients with EGFR mutation, progression-free survival (PFS) was
http://dx.doi.org/10.1016/j.lungcan.2015.07.006
0169-5002/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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signiﬁcantly longer and the response rate was signiﬁcantly higher
with geﬁtinib than with platinum-based doublet chemotherapy.
Further, patients receiving geﬁtinib had a lower incidence of
severe adverse events compared to those receiving chemotherapy.
Nevertheless, the ﬁnal results of IPASS conﬁrmed that there
was no difference in overall survival (OS) between geﬁtinib
and carboplatin–paclitaxel (CBDCA+PTX) [14]. On the basis of
this evidence, the Pharmaceuticals and Medical Devices Agency
(PMDA) approved revised labeling for geﬁtinib that limited its
indications to locally advanced or metastatic NSCLC patients with
EGFR mutations in 2011.
The Japanese national health insurance system provides uni-
versal coverage to all citizens. However, as in other developed
countries, burgeoningmedical costs causedby theagingpopulation
and the evolution of novel but costly health care technologies is an
emerging social problem. The medical costs for cancer treatment
continues to increase, and at about JP¥3812 billion (US$37 billion;
US$1= JP¥104 as of February 2014) represented 13.5% of all medi-
cal costs in 2012 [15]. The current labeling for geﬁtinib for NSCLC
requires EGFR mutation testing for all patients to identify eligible
treatment candidates. It is therefore important to justify this addi-
tional cost. To our knowledge, however, no such cost-effectiveness
analysis of geﬁtinib has yet been conducted in Japan.
Here, we evaluated the cost-effectiveness of combination use of
geﬁtinib and EGFR mutation testing as ﬁrst-line therapy for NSCLC
patients in Japan.
2. Methods
2.1. Decision model structure
We compared the cost-effectiveness of the two treatment
strategies from the perspective of healthcare payer (Fig. 1). In the
‘EGFR-testing strategy’ (strategy 1), testing for EGFR mutations
was performed before treatment was determined; patients who
tested positive for EGFR mutation received geﬁtinib as ﬁrst-line
treatment, and those who tested negative received CBDCA+PTX
as ﬁrst-line treatment. We assumed that 32% of patients tested
positive [16]. In the ‘no EGFR-testing strategy’ (strategy 2),
genetic testing was not conducted, and all patients were treated
with CBDCA+PTX. The treatment-related costs and outcomes for
patients without EGFR mutation in both strategies were assumed
tobe the sameas theyall receivedCBDCA+PTXasﬁrst-line therapy.
Therefore, only the EGFR testing fee was included as the difference
in the two treatment strategies.
Themeasure of this cost-effectiveness analysiswas incremental
cost-effectiveness ratio (ICER). Quality-adjusted life-years (QALYs)
gained was used as an outcome to calculate the ICER. In this anal-
ysis, willingness-to-pay (WTP) was set to JP¥5.0 million to 6.0
million (US$48,100 to 57,700) for one additional QALY based on
a Japanese study [17]. We adopted a 2% discount rate per year for
both costs and outcomes [18].
Fig. 1. Treatment strategies evaluated in this analysis. CBDCA+PTX, carboplatin–
paclitaxel; EGFR, epidermal growth factor receptor; M, Markov model.
2.2. Patients and treatment
For this analysis, the base-case patient population was assumed
to be Japanese patients who were 18 years of age or older, had
histologically conﬁrmed stage IIIB or IV NSCLC with an ECOG per-
formance status from 0 to 2, and had no history of chemotherapy.
The patients were assumed to receive either of the therapies
below according to the Japanese drug package inserts, identical to
the regimen used in IPASS:
• geﬁtinib (250mg/day, administered orally) until disease progres-
sion,
• paclitaxel (200mg/m2, administered intravenously) followed by
carboplatin (at a dose calculated to produce an area under the
concentration-time curve of 6.0mg/ml/min, administered intra-
venously) in cycles of once every 3 weeks up to 6 cycles.
2.3. Disease modeling
We constructed theMarkovmodel including three health states
for analysis: progression-free survival, progressive disease, and
death (Online Data Supplement Fig. 1). Patients move from one
state to another during each cycle length of 3 weeks. The time
horizon of 5 years was adopted to reﬂect the limited remaining
life of the patients. Weibull curves were extrapolated to ﬁt to
Kaplan–Meier survival curves of IPASS [10,14]. The scale param-
eter () and shape parameter () were estimated using SAS
9.3 software (SAS Institute Inc., Cary, NC, USA). These parame-
ters were used to measure the probabilities of transition at the
time point of cycle t, according to the following formula [19]:
P(t) = 1− exp[(t−1) − t ]. The ﬁttedWeibull curves for patients
with EGFR mutation and the estimated parameters are provided in
the Online Data Supplement Fig. 2 and Table 1.
2.4. Costs and utility
Costs were estimated from the health care payer’s perspec-
tive; therefore, only direct medical costs were included. The
medical costs considered in this model included drugs, outpa-
tient chemotherapy, EGFR testing, disease monitoring and hospital
administration (Table 1). To calculate the cost of each drug, we
assumed a body surface area of 1.73m2 and glomerular ﬁltration
rate of 97.6ml/min based on the median age of patients in IPASS
[10]. For the ﬁrst cycle of treatment, the patients were consid-
ered to be hospitalized. Premedication for CBDCA+PTX consisting
of dexamethasone, granisetron, ranitidine, and diphenhydramine
was to be used according to the regimen used at the Cancer Insti-
tute Hospital of the Japanese Foundation of Cancer Research (JFCR)
[20]. Treatment regimens used after disease progression in IPASS
varied, as they were at the physician’s discretion. Therefore, we
applied the costs of docetaxel monotherapy after disease progres-
sion as the base case. The costs of terminal and best supportive care
were expected to be the same in both strategies, so they were not
included in this analysis. Costs were calculated according to the
Japanese 2012 drug tariff and medical care based on fee for service
[21,22].
Because health utility measurements were not available in
IPASS, utility scores for each state were adapted from other litera-
ture [23,24]. In our study, utility values were adjusted according to
response rate, types of Common Terminology Criteria (CTC) grade
3/4 adverse events, route of administration and disease progres-
sion (Table 2). CTC grade 2 hair loss was also included as it has been
reported to have a deleterious impact on health-related quality of
life (HRQoL) [23–25].
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Table 1
Costs and number of times of healthcare services per patient cycle.
Parameter Unit cost (JP¥ [US$]) Geﬁtinib Carboplatin +paclitaxel Subsequent therapy
1st cycle Subsequent cycle 1st cycle 2nd to 6th cycle After 6th cycle
Drug costs [21]
Geﬁtinib 6526.2 [62.8] 21 21
Carboplatin 66,806 [642.3] 1 1
Paclitaxel 112,043 [1077.3] 1 1
Premedication 7464.5 [71.8] 1 1
Subsequent treatmenta 111,895 [1075.9] 1
Outpatient chemotherapy [22]
Outpatient service fee 690 [6.6] 1 1 1 1
Prescription fee 420 [4.0] 1
Prescription fee for anticancer drug 700 [6.7] 0.75
Outpatient chemotherapy 5800 [55.8] 1 1
Intravenous drip fee 950 [9.1] 1 1 1
Preparation in sterile environment 500 [4.8] 1 1 1
EGFR testing fee [22] 21,000 [201.9] 1
Disease monitoring [22]
Blood drawing fee 160 [1.5] 1 1 1 1
Peripheral blood test fee 210 [2.0] 1 1 1 1 1 1
Peripheral blood test diagnostic fee 1250 [12.0] 0.75 0.75 0.75 0.75 0.75 0.75
Biochemical test fee 1210 [11.6] 1 1 1 1 1 1
Biochemical test diagnostic fee 1440 [13.8] 0.75 0.75 0.75 0.75 0.75 0.75
Tumor marker test fee 4000 [38.5] 0.75 0.75 0.75 0.75 0.75 0.75
CT scan with a contrast medium 14,500 [139.4] 0.5 0.5 0.5 0.5 0.5 0.5
CT scan diagnostic fee 4500 [43.3] 0.75 0.75 0.75 0.75 0.75 0.75
Hospital fee [22]
From 1st to 14th day 20,160 [193.8] 14 14
From 15th day 17,580 [169.0] 7 7
Total (JP¥[US$]/cycle) 580,413 [5580.9] 155,908 [1499.1] 610,126 [5866.6] 211,476 [2033.4] 17,913 [172.2] 137,058 [1317.9]
CT, computed tomography; EGFR, epidermal growth factor receptor.
a The cost of docetaxel therapy (60mg/m2 per cycle) was used in the base-case.
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Table 2
Base case values and ranges for sensitivity analysis of parameters.
Variable Value Range Reference
EGFR mutation rate (%) 32 10/60 [16]
Discount rate (%/year) 2 0/7 [18]
Time horizon (year) 5 3/10 [23]
Health utilities
Baseline utility 0.6532 0.6096/0.6968a [24]
Response (utility increment) 0.0193 0.0065/0.0321a [24]
Utility decrement
Disease progression 0.1798 0.1373/0.2223a [24]
Grade 3/4 neutropenia 0.0897 0.0595/0.1200a [24]
Grade 3/4 febrile neutropenia 0.0900 0.0580/0.1220a [24]
Grade 3/4 fatigue 0.0743 0.0373/0.1097a [24]
Grade 3/4 nausea & vomiting 0.0480 0.0163/0.0797a [24]
Grade 3/4 diarrhea 0.0466 0.0164/0.0772a [24]
Hair loss (partial or complete) 0.0450 0.0160/0.0740a [24]
Grade 3/4 rash 0.0325 0.0095/0.0555a [24]
Grade 3/4 anemia 0.0743 0.0373/0.1097a [23]
Intravenous therapy 0.0425 0.0032/0.0818a [23]
Oral therapy 0.0139 0.0000/0.0367a [23]
EGFR, epidermal growth factor receptor.
a Upper and lower 95% CI.
2.5. Sensitivity analysis
Several sensitivity analyses were performed to evaluate the
uncertainty and robustness of themodel. One-way sensitivity anal-
ysis assessed the impact of varying key model parameters on the
ICER. Costs were varied within a range of ±20% except for the cost
of subsequent therapy, which was varied by ±50% due to its high
variability. The rangesof other keyparameters are shown inTable2.
Probabilistic sensitivity analysis was also performed to assess the
impact on model parameter uncertainty using a Monte Carlo simu-
lationwith 10,000 iterations. Themodel used a normal distribution
with a coefﬁcient of variation of 0.4 for costs and beta distribution
for utility values [19].
Further,we carried out several scenario analyses. In theﬁrst sce-
nario, a hazard ratio (HR) of PFS estimated by meta-analysis of the
four phase 3 trials was applied to derive the PFS curve for patients
treated with geﬁtinib [26]. In the second scenario, we considered
the case that generic drugs were used for CBDCA+PTX. As several
generic drugs with different prices are available for this treat-
ment, we estimated the generic substitution price as the weighted
average price of the drugs based on the actual prescriptiondistribu-
tion. We used the large-scale hospital information database which
include the administration and health insurance claims records
from more than 150 secondary care hospitals around Japan since
2008 [27]. In the third scenario, pemetrexed was used after dis-
ease progression, as it has been widely used in recent years. The
cost of pemetrexed monotherapy per cycle was estimated to be
JP¥352,820 (US$3,392.5) according to the Japanese drug tariff and
the regimenusedat theCancer InstituteHospital of the JFCR [20,21].
This value was applied for the cost of subsequent treatments to
assess the robustness of the model.
3. Results
3.1. Base-case analysis
The results of the base-case analysis are shown in Table 3.When
EGFR testingwas performed for all eligible patients before ﬁrst-line
therapy, expected incremental costs and effectiveness were esti-
mated to be about JP¥122,000 (US$1180; corresponding to 6.6%
increase in geﬁtinib armvs. carboplatin–paclitaxel) and0.036QALY
per patient. The ICER of the EGFR-testing strategy compared with
the no-testing strategywas calculated to be approximately JP¥3.38
million (US$32,500) per QALY gained. This was lower than the
threshold of JP¥5.0 million to 6.0 million (US$48,100–57,700) [17].
3.2. Sensitivity analysis
The results of one-way sensitivity analyses are presented in a
tornado diagram (Fig. 2). The price of geﬁtinib had the greatest
impact on the ICERwhen itwas variedwithin the predeﬁned range.
The ICER exceeds the threshold value of JP¥6.0 million per QALY
when the price of geﬁtinib increases to JP¥7595.2 (US$73.0). The
other inﬂuential variables included the cost of treatment after pro-
gression, cost of CBDCA+PTX treatment and EGFR mutation rate.
The probabilistic sensitivity analysis found that more than 90% of
the results of 10,000 simulations fellwithin the ﬁrst quadrant (test-
ing strategy results in QALYs gained with additional costs), while
Table 3
Results of cost-effectiveness analysis.
Group Cost per patient
(JP¥million[US$1000])
Effectiveness
(QALYs gained)
ICER
(JP¥million[US$1000]/QALY)
Strategy 1 (Testing)
EGFR positive 5.47 [52.6] 1.180
EGFR negative a+0.021 [a+0.2] b
Strategy 2 (No-testing)
(EGFR positive) 5.13 [49.4] 1.067
(EGFR negative) a b
Comparison Incremental cost Incremental effectiveness
Strategy 1 vs. Strategy 2 0.122 [1.18] 0.036 3.38 [32.5]
a, b=Not estimated as these values were to be offset in calculating the ICER.
EGFR, epidermal growth factor receptor; QALY, quality-adjusted life years; ICER, incremental cost-effectiveness ratio.
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Fig. 2. Tornado diagram for one-way sensitivity analyses. CBDCA+PTX, carboplatin–paclitaxel; EGFR, epidermal growth factor receptor.
the other simulation results were located in the fourth quadrant
(testing strategy results in QALYs gained at reduced costs) (Fig. 3).
The probability that the testing strategywas cost-effectivewas 89%
at a threshold value of JP¥5.0 million (US$48,100) per QALY gained
(cases under the dotted line, Fig. 3), and 97% at a threshold value
of JP¥6.0 million (US$57,700) per QALY gained (cases under the
broken line, Fig. 3).
In the ﬁrst scenario analysis, the overall costs and QALYs of
the EGFR-testing strategy increased when the HR of PFS estimated
by meta-analysis of the four phase 3 trials was applied [26]. The
ICER was calculated to be JP¥3.24 million (US$31,100) per QALY
and ranged between JP¥3.08 and 3.46 million (US$29,600–33,300)
per QALY when the 95% CI was applied. In the second scenario
when the use of generic drugs was considered, the expected costs
of CBDCA+PTX treatment were determined to be JP¥141,229.6
(US$1358.0) per cycle, while the cost of the no-testing strategy
decreased, and thus the incremental cost increased. In this sce-
nario, the ICER was JP¥5.16 million (US$49,600) per QALY and
still remained within the threshold values. In the third scenario
usingpemetrexed as subsequent treatment, the cost of pemetrexed
turned out to be higher than the cost of geﬁtinib per cycle in this
setting. The ICER was −JP¥4.23 million (−US$40,600) per QALY,
Fig. 3. Incremental cost-effectiveness scatter plot for probabilistic sensitivity analyses. QALY, quality-adjusted life year; WTP, willingness to pay; dotted line: threshold of
JP¥5.0 million/QALY (US$48,100/QALY); broken line: threshold of JP¥6.0 million/QALY (US$57,700/QALY).
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showing that the EGFR-testing strategy is dominant (lower costs
and greater effectiveness) relative to the no-testing strategy.
4. Discussion
We conducted a cost-effectiveness analysis of the combination
use of EGFR mutation testing and geﬁtinib as ﬁrst-line therapy for
NSCLC patients from the point of view of the Japanese healthcare
payer.Our analysis shows that the ICERof theEGFR-testing strategy
compared with the no-testing strategy is expected to be around
JP¥3.38 million (US$32,500) per QALY gained. This result suggests
that the combination use of EGFR mutation testing and geﬁtinib as
ﬁrst-line therapy for NSCLC patients is cost-effective in Japan.
In our analysis, the EGFR testing strategy increased costs by
JP¥122,000 (US$1180) per patient. According to the Center for Can-
cer Control and Information Services [28,29], the expected number
of new lung cancer patients in Japan is 129,500 in 2014 and approx-
imately 40% of those are estimated to be stage IIIB or IV patients.
If we assume the annual number of new eligible patients to be
50,000 in Japan, the budget impact would be as large as JP¥6.10
billion (US$58.7 million) per year. The incremental effectiveness
of the EGFR testing strategy was 0.036 QALYs. Considering the
effect of therapy from a patient perspective, the beneﬁt in QoL
is important. The effect on better QoL is likely ascribable to the
lower treatment burden of oral administration in an outpatient
setting and the better treatment outcome in PFS prolongation,
both of which allow patients more time to spend with family and
more opportunities to work in their remaining life. Further, conse-
quential social impact would not be negligible, and would include
the amelioration of loss of working productivity and lower uti-
lization of limited medical resources. Thus, despite the lack of OS
beneﬁt and large additional cost, the EGFR testing strategy is rec-
ommended in Japan as it improves patient QALY in a cost-effective
way.
In the United Kingdom, the National Institute for Health and
Clinical Excellence (NICE) assessed the cost-effectiveness of ﬁrst-
line geﬁtinib versus chemotherapy in patients with advanced or
metastatic NSCLC [23]. Based on the calculated ICER range of
GB£20,100 to over 70,000 (US$33,000–115,000; UK£1=US$1.64 as
of February 2014) per QALY gained, NICE recommended geﬁtinib
as an option for the ﬁrst-line treatment of EGFR mutation-positive
advanced or metastatic NSCLC patients provided that geﬁtinib is
procured at the agreed ﬁxed price. Although the analysis con-
ducted by NICE was based on an interim analysis of IPASS, our
analysis, based on the ﬁnal analysis in a different setting, reached
similar results. A cost-effectiveness study conducted in Singapore
by de Lima Lopes et al. [30] demonstrated that EGFR testing and
ﬁrst-line treatment with geﬁtinib had lower costs and greater
QALYs than standard care. Even though Singaporean analysis
used a non-Markov economic model and was based on different
cost assumptions, its ﬁndings regarding incremental QALYs were
strikingly similar to those with our own model, supporting its
robustness.
In our one-way sensitivity analyses, the price of geﬁtinib was
shown to have the greatest inﬂuence on the results. In Japan, drug
pricing is determinedby the governmental drug tariff,which is sub-
ject to regular biennial revision. The ICER remained cost-effective
when the original price of geﬁtinib in 2002, JP¥7216 (US$69.4) was
applied. The EGFR mutation rate was also shown to be a sensi-
tive parameter in this analysis. The prevalence of EGFR mutation
in Western populations is around 14%, which is lower than in Asian
populations [31]. When the percentage of EGFR mutation-positive
patients decreases to 10%, the ICER remained below the acceptable
threshold value, suggesting that the results can also be applied to
Caucasians under the Japanese health insurance system.
EGFR testing was listed on the National List for reimbursement
at the price of JP¥20,000 (US$192), as determined by the regulatory
authority in 2011. This price is almost half that in other countries.
Although the price was increased to JP¥21,000 (US$202) in 2012,
it was considered uncertain whether this price was appropriate. In
our analysis, varying the cost of EGFR testing did not have a big
inﬂuence on the cost-effectiveness of the EGFR testing strategy.
As the Japanese pricing system is not value-based, a transparent
approach with a more scientiﬁc basis is warranted for such emerg-
ing innovative technologies [32].
Our ICER results which took account of the case of generic
substitution may be overestimated. In 2013, generic drug prescrip-
tion in Japan accounted for only 9.5% of total anti-cancer drug
expenditures [33]. In the database we used, however, the percent-
age of generic drug prescriptions in the total cost of CBDCA+PTX
treatment was 61.9%. This discrepancy occurred because our pre-
scription data were derived from secondary care hospitals, which
prescribe generic drugs more frequently than the national average
due to adoption of Diagnosis-Procedure Combination lump-sum
payment system. Therefore, the expected cost of CBDCA+PTX in
our analysis would be lower than the estimates based on the
national proportion of generic substitution, which further supports
the cost-effectiveness of EGFR-testing strategy.
There are several limitations in this analysis. First, because of
a lack of utility data for Japanese patients, we extrapolated British
utility scores. Although the sensitivity analyses showed that our
results were not greatly inﬂuenced by varying these values, a sur-
vey of Japanese utility scores is warranted. Our model can be
updated when detailed utility scores for Japanese NSCLC patients
become available. Second, we assumed the same treatment with
docetaxel after disease progression in both strategies. While the
platinum-baseddoublet chemotherapy is a standardﬁrst-line ther-
apy for NSCLC in Japan, this assumption might not reﬂect the real
situation since the use of platinum-based doublet chemotherapy
is also possible after ﬁrst-line EGFR-TKI. Further, the second or
third-line use of EGFR-TKI therapy is available in Japan, such as
geﬁtinibanderlotinib, however, it isnot included inourmodel since
the treatment guideline by the Japan Lung Cancer Society highly
recommends EGFR mutation testing to be conducted before deter-
mining ﬁrst-line therapy [34]. Additionally, lack of head-to-head
trial data comparing geﬁtinib with the other EGFR-TKIs includ-
ing erlotinib and the recently approved afatinib (expected cost
per cycle: JP¥223,495 (US$2,149.0) and JP¥235,169 (US$2261.2),
respectively [21]), as aﬁrst-line therapydidnot allowus to evaluate
incremental effectiveness. Another current standard treatments,
pemetrexed plus cisplatin or CBDCA, and the addition of beva-
cizumab toﬁrst-linedoublet chemotherapy,werenot considered in
our analysis. The costs of pemetrexed andbevacizumabare approx-
imately JP¥352,820 (US$3392.5) and JP¥450,666 (US$4333.3) per
cycle, respectively [21]. The cost-effectiveness analyses of regi-
mens including pemetrexed and bevacizumab arewarrantedwhen
the head-to-head trial data with these compared with geﬁtinib
becomes available, which is essential for valid economic modeling.
However, we believe that the combination use of EGFR mutation
testing and geﬁtinib would most likely be cost saving strategy
considering themuch higher cost of pemetrexed and bevacizumab.
The rise in medical costs is becoming an important issue world-
wide. Although new molecular drugs are being developed, patient
access to these drugs may be limited due to their high cost. There-
fore, it is important to individualize effective treatment targeting
by genetic testing or other methods. Our analysis showed that the
combination use of EGFR testing and geﬁtinib for ﬁrst-line NSCLC is
cost-effective in Japan. Cost-effectiveness analysis in the decision-
making process can help clarify the relationship between the cost
and social value of new innovative technology to determine appro-
priate treatment strategies. We believe that our present analysis
Y. Narita et al. / Lung Cancer 90 (2015) 71–77 77
can serve as an important reference for health policy decisionmak-
ers.
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